@article{10902/36647,
year = {2025},
url = {https://hdl.handle.net/10902/36647},
abstract = {The European Renal Association (ERA) Registry collects data on kidney replacement therapy (KRT) in patients with end-stage kidney disease (ESKD). This paper summarizes the ERA Registry Annual Report 2022, with a special focus on comparisons by sex. The supplement of this paper contains the complete ERA Registry Annual Report 2022. Data was collected from 53 national and regional KRT registries from 35 countries. Using this data, incidence, and prevalence of KRT, kidney transplantation rates, survival probabilities, and expected remaining lifetimes were calculated. In 2022, 530 million people of the European general population were covered by the ERA Registry. The incidence of KRT was 152 per million population (pmp). In incident patients, 54% were 65 years or older, 64% were male, and the most common primary renal disease (PRD) was diabetes mellitus (22%). At KRT initiation, 83% of patients received haemodialysis, 12% received peritoneal dialysis, and 5% underwent pre-emptive kidney transplantation. On 31 December 2022, the prevalence of KRT was 1074 pmp. In prevalent patients, 48% were 65 years or older, 62% were male, the most common PRD was of miscellaneous origin (18%), 56% of patients received haemodialysis, 5% received peritoneal dialysis, and 39% were living with a functioning graft. In 2022, the kidney transplantation rate was 40 pmp, with most kidneys coming from deceased donors (66%). For patients starting KRT between 2013 to 2017, 5-year survival probability was 52%. Compared with the general population, the expected remaining lifetime was 66% and 68% shorter for males and females, respectively, receiving dialysis, and 46% and 49% shorter for males and females, respectively, living with a functioning graft.},
organization = {The ERA Registry is funded by the European Renal Association
(ERA). This article was written by R. Boenink et al. on behalf
of the ERA Registry, which is an official body of the ERA. N.M.
reports being board member for the NICE guidelines and Cyprus
Renal Association. M.M.V. reports receiving grants from Instituto
de Salud Carlos; consulting fees, payment for lectures, support
for attending meetings and/or travel from Novo-Nordisk, Astra
Zeneca, Boherinheim, Ingelheim-Lilly, Bayer, Menarini, Vifor;
and is president of the Nephrology Madrilenian Society. A.M.D.S. ´
reports being board member for the Voivodeship Consultant
for Nephrology. M.F.S.R. reports receiving consulting fees from
Fresenius, Baxter, Nipro; payment for lectures from Baxter,
Fresenius, Physidia; and support for attending meetings and/or
travel from Vifor, Fresenius, NovoNordisk; and is board member
of Fresenius European Home Dialysis Advisory Board and the
Direction Committee of the Spanish Society of Nephrology.
M.O.V. reports receiving consulting fees of SANOFI and support
for attending meetings and/or travel by Fressenius and Sandoz.
A.Å. reports receiving grants from Oripharm and AstraZeneca;
payments from Oripharm and Glenmark; and receipt of study
drug from AstraZeneca. I.R. reports being president of the Czech
Society of Nephrology and Secretary-Treasurer of ERA 2017-
2024. M.O.R. reports payment for lectures from AstraZeneca; and
is board member of AstraZeneca, ISN Eastern & Central Europe
Regional Board, Ministry of Social Affairs of Estonia, and Nordic
Peritoneal Dialysis Council. A.O. has received grants from Sanofi;
is director of the Catedra Mundipharma-UAM of diabetic kidney
disease and the Catedra AstraZeneca-UAM of chronic kidney
disease and electrolytes; has received consultancy or speaker
fees or travel support from Advicciene, Astellas, AstraZeneca,
Amicus, Amgen, Fresenius Medical Care, GSK, Boehringer Ingelheim, Bayer, Sanofi-Genzyme, Menarini, Kyowa Kirin,
Alexion, Idorsia, Chiesi, Otsuka, Sysmex, Novo-Nordisk, and Vifor Fresenius Medical Care Renal Pharma; and is board member
of ERA council and SOMANE. K.J.J. reports receiving funds from
European Renal Association and European Society for Paediatric
Nephrology, and is board member of SHARE RR working group.
V.S.S. reports having support for the present manuscript from
European Renal Association. All other co-authors declare that
they have no relevant financial interests.},
publisher = {Oxford University Press},
publisher = {Clinical Kidney Journal, 2025, 18(2), sfae405},
title = {The ERA registry annual report 2022: epidemiology of kidney replacement therapy in Europe, with a focus on sex comparisons},
author = {Boenink, Rianne and Bonthuis, Marjolein and Boerstra, Brittany A. and Astley, Megan E. and Montez de Sousa, Iris R. and Helve, Jaakko and Komissarov, Kirill S. and Comas, Jordi and Radunovic, Danilo and Buchwinkler, Lukas and Hommel, Kristine and Gjorgjievski, Nikola and Galvão, Ana A and Mitsides, Nicos and Vidas, Maria Marques and Debska Slizien, Alicja M. and Ambrus, Csaba and Slon-Roblero, Maria F. and Tten Dam, Marc A.G.J. and Valentín Muñoz, María de la Oliva},
}